Articles By Estel Grace Masangkay

  1. Pharmacyclics' Imbruvica Shows Potential In Multiple Myeloma 12/10/2014

    Pharmacyclics reported new Phase 2 data for Imbruvica (ibrutunib) as treatment for relapsed or relapsed/refractory multiple myeloma (MM).

  2. Novartis Posts Positive CTL019 Data In r/r ALL 12/10/2014

    Novartis revealed strong clinical data for its investigational chimeric antigen receptor (CAR) therapy CTL019 as treatment for relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

  3. Genmab, Janssen To Study Daratumumab In 3 NHL Types 12/9/2014

    Genmab announced that its partner Janssen Biotech is preparing to launch a Phase 2 trial for daratumumab as treatment for three different types of non-Hodgkin’s lymphomas (NHL), namely diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).

  4. ChemoCentryx Drug Wins EU Orphan Status In Rare Vasculitis 12/9/2014

    Clinical stage biopharmaceutical firm ChemoCentryx announced it has received Orphan Medicinal Product designation from the European Commission for CCX168 as treatment for two forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).

  5. Tesaro, AnaptysBio Expand Immuno-Oncology Partnership 12/8/2014

    Oncology-focused biopharma firm Tesaro and privately-held therapeutic antibody firm AnaptysBio announced that the companies are expanding their immuno-oncology partnership and exclusive license agreement with the development of a new bispecific antibody lead targeting two unnamed immune checkpoints.

  6. FDA OKs Sanofi's Priftin For Latent TB Infection 12/8/2014

    Sanofi announced that the U.S. Food and Drug Administration (FDA) has approved Priftin (rifapentine) in combination with isoniazid (INH) as treatment for latent tuberculosis infection (LTBI) in patients two years old and above who are also at high risk of developing tuberculosis (TB).

  7. Novartis Posts Phase 3 Data For Gilenya In MS 12/5/2014

    Novartis reported the latest findings from the Phase 3 trial of its drug Gilenya (fingolimod) in primary progressive multiple sclerosis (PPMS), a difficult form of multiple sclerosis.

  8. Genzyme Launches Lemtrada For MS In U.S. 12/5/2014

    Sanofi company Genzyme announced it has launched its newly approved drug Lemtrada (alemtuzumab) as treatment for multiple sclerosis in the U.S.

  9. Actinium Wins FDA Orphan Status For AML Drug 12/5/2014

    Biopharma firm Actinium Pharmaceuticals announced it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Actimab-A as treatment for newly diagnosed AML patients older than 60 years old.

  10. AstraZeneca, CRUK Link Arms To Screen For New Cancer Drugs 12/4/2014

    British drug maker AstraZeneca and Cancer Research UK have expanded their ongoing collaborative relationship with their latest agreement to screen new cancer drug leads at the AstraZeneca MRC UK Centre for Lead Discovery, a new center to be built in Cambridge.